Prentiss Smith & Co. Inc. Decreases Position in REGENXBIO Inc. (NASDAQ:RGNX)

Prentiss Smith & Co. Inc. cut its position in REGENXBIO Inc. (NASDAQ:RGNX) by 10.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,107 shares of the biotechnology company’s stock after selling 1,133 shares during the period. Prentiss Smith & Co. Inc.’s holdings in REGENXBIO were worth $181,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of RGNX. Harbor Capital Advisors Inc. raised its holdings in shares of REGENXBIO by 10.1% during the third quarter. Harbor Capital Advisors Inc. now owns 48,559 shares of the biotechnology company’s stock valued at $799,000 after purchasing an additional 4,453 shares during the last quarter. Raymond James & Associates raised its holdings in shares of REGENXBIO by 405.3% during the third quarter. Raymond James & Associates now owns 100,620 shares of the biotechnology company’s stock valued at $1,656,000 after purchasing an additional 80,706 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of REGENXBIO by 77.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 114,962 shares of the biotechnology company’s stock valued at $1,892,000 after purchasing an additional 50,056 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of REGENXBIO by 47.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,540 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 3,379 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of REGENXBIO by 8.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 208,307 shares of the biotechnology company’s stock valued at $3,429,000 after purchasing an additional 15,794 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RGNX has been the subject of several research reports. Raymond James reissued an “outperform” rating and set a $45.00 price objective on shares of REGENXBIO in a report on Wednesday, February 21st. Barclays upped their target price on shares of REGENXBIO from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. Wedbush reaffirmed a “neutral” rating and set a $21.00 target price on shares of REGENXBIO in a report on Wednesday, February 28th. Leerink Partnrs raised shares of REGENXBIO from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 6th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.45.

REGENXBIO Trading Up 0.1 %

RGNX traded up $0.02 during trading on Thursday, hitting $16.06. 604,238 shares of the company traded hands, compared to its average volume of 719,818. The company has a market cap of $787.58 million, a PE ratio of -2.66 and a beta of 1.29. The stock’s 50-day simple moving average is $19.97 and its two-hundred day simple moving average is $17.85. REGENXBIO Inc. has a 1 year low of $11.83 and a 1 year high of $28.80.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.16). The company had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The business’s revenue was down 28.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.38) earnings per share. Equities analysts expect that REGENXBIO Inc. will post -3.98 EPS for the current year.

Insider Activity at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 12,878 shares of REGENXBIO stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the transaction, the insider now directly owns 107,192 shares of the company’s stock, valued at approximately $3,039,965.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other REGENXBIO news, insider Steve Pakola sold 12,878 shares of REGENXBIO stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the transaction, the insider now directly owns 107,192 shares of the company’s stock, valued at approximately $3,039,965.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $21.86, for a total transaction of $327,900.00. Following the completion of the transaction, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at $8,919,645.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,878 shares of company stock valued at $1,217,370. Corporate insiders own 13.13% of the company’s stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.